MARKER THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.78 USD | +14.77% |
|
+37.75% | -13.09% |
| 15/05 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
| 15/05 | Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Capitalization 1 | 131.7 | 69.64 | 78.94 | 22.71 | 42.63 | - | - |
| Enterprise Value (EV) 1 | 131.7 | 69.64 | 78.94 | 22.71 | 42.63 | 42.63 | 42.63 |
| P/E ratio | -6.13 x | -2.38 x | -1.73 x | -0.74 x | -2.91 x | -3.59 x | -3.98 x |
| Yield | - | - | - | - | - | - | - |
| Capitalization / Revenue | 618 x | 149 x | 63.6 x | 2.52 x | 34.3 x | - | - |
| EV / Revenue | 618 x | 149 x | 63.6 x | 2.52 x | 34.3 x | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| EV / FCF | -7.06 x | - | -2.6 x | - | -2.37 x | -1.42 x | -0.93 x |
| FCF Yield | -14.2% | - | -38.5% | - | -42.2% | -70.4% | -108% |
| Price to Book | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 4,572 | 4,803 | 8,308 | 8,540 | 8,919 | - | - |
| Reference price 2 | 28.80 | 14.50 | 9.502 | 2.659 | 4.780 | 4.780 | 4.780 |
| Announcement Date | 12/03/20 | 09/03/21 | 17/03/22 | 22/03/23 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.2132 | 0.4668 | 1.242 | 9.014 | - | 1.244 | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -22.53 | -28.89 | -39.48 | - | - | -22.47 | -33.2 | -41.77 |
| Operating Margin | -10,567.48% | -6,188.18% | -3,179.33% | - | - | -1,806.43% | - | - |
| Earnings before Tax (EBT) 1 | -21.43 | -28.71 | -41.88 | - | -14.04 | -21.75 | -32.65 | -41.25 |
| Net income 1 | -21.43 | -28.71 | -41.88 | - | -8.237 | -21.75 | -32.65 | -41.25 |
| Net margin | -10,051.11% | -6,149.68% | -3,372.68% | - | - | -1,748.31% | - | - |
| EPS 2 | -4.700 | -6.100 | -5.500 | -3.580 | - | -1.640 | -1.330 | -1.200 |
| Free Cash Flow 1 | -18.66 | - | -30.41 | - | - | -18 | -30 | -46 |
| FCF margin | -8,752.42% | - | -2,449.11% | - | - | -1,446.95% | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/03/20 | 09/03/21 | 17/03/22 | 22/03/23 | 25/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.242 | 0.9643 | 0.7905 | 3.95 | 3.309 | 1.244 | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -9.764 | -9.795 | -9.28 | -7.019 | - | -2.549 | -3.984 | -6.93 | -9.009 |
| Operating Margin | -786.36% | -1,015.72% | -1,173.92% | -177.72% | - | -204.9% | - | - | - |
| Earnings before Tax (EBT) 1 | -9.763 | -9.911 | -9.244 | -6.92 | - | -2.393 | -3.856 | -6.845 | -8.654 |
| Net income 1 | -9.763 | -9.911 | -9.244 | -6.92 | - | -2.393 | -3.856 | -6.845 | -8.654 |
| Net margin | -786.28% | -1,027.72% | -1,169.4% | -175.2% | - | -192.34% | - | - | - |
| EPS 2 | -1.100 | -1.200 | -1.100 | -0.8000 | -3.270 | -0.2700 | -0.4300 | -0.4900 | -0.4500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - |
| Announcement Date | 17/03/22 | 13/05/22 | 11/08/22 | 10/11/22 | 22/03/23 | 15/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -18.7 | - | -30.4 | - | - | -18 | -30 | -46 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.37 | - | - | - | - | - | 0.78 | 2.33 |
| Capex / Sales | 175.89% | - | - | - | - | - | - | - |
| Announcement Date | 12/03/20 | 09/03/21 | 17/03/22 | 22/03/23 | 25/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.78
USD
Average target price
11
USD
Spread / Average Target
+130.13%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -13.09% | 42.63M | |
| +38.66% | 52.85B | |
| -7.81% | 38.87B | |
| +35.54% | 38.24B | |
| -10.77% | 26.79B | |
| +11.77% | 26.16B | |
| -17.82% | 19.9B | |
| +35.09% | 13.18B | |
| +29.17% | 12.24B | |
| -3.05% | 11.79B |
- Stock Market
- Equities
- MRKR Stock
- Financials Marker Therapeutics, Inc.
